Life Science Investing OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
Life Science Investing OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
TomaGold Intercepts 6.68% ZnEq (1.57 g/t AuEq) over 48.05 Metres, including 39.03% ZnEq (9.15 g/t AuEq) over 2.90 Metres at Berrigan Mine and Identifies a Major Hydrothermal Footprint
Apollo Silver Announces Correction to Warrant Terms of $25 Million Strategic Investment by Eric Sprott and Jupiter Asset Management
